Works matching AU Ferrero, S.

Results: 173
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM‐CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.

    Published in:
    HemaSphere, 2022, v. 6, p. 1032, doi. 10.1097/01.HS9.0000847444.51476.b0
    By:
    • Ladetto, M.;
    • Tavarozzi, R.;
    • Evangelista, A.;
    • Zanni, M.;
    • Tucci, A.;
    • Anastasia, A.;
    • Botto, B.;
    • Boccomini, C.;
    • Bolis, S.;
    • Volpetti, S.;
    • Zilioli, V. R.;
    • Puccini, B.;
    • Arcari, A.;
    • Pavone, V.;
    • Gaidano, G.;
    • Corradini, P.;
    • Tani, M.;
    • Ferrero, S.;
    • Cavallo, F.;
    • Milone, G.
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐IPI): A PROGNOSTIC SCORE FOR THE ENTIRE SPECTRUM OF MARGINAL ZONE LYMPHOMAS. A FIL AND SPORE‐MER STUDY.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 102, doi. 10.1002/hon.3163_63
    By:
    • Luminari, S.;
    • Bommier, C.;
    • Fabbri, N.;
    • Nizzoli, M. E.;
    • Maurer, M. J.;
    • Tarantino, V.;
    • Ferrero, S.;
    • Rattotti, S.;
    • Merli, M.;
    • Ferrari, A.;
    • Murru, R.;
    • Khurana, A.;
    • Mwangi, R.;
    • Deodato, M.;
    • Del Giudice, I.;
    • Cencini, E.;
    • Re, F.;
    • Visco, C.;
    • Feldman, A. L.;
    • Link, B. K.
    Publication type:
    Article
    33

    COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 183, doi. 10.1002/hon.3163_115
    By:
    • Ferrero, S.;
    • Assanto, G. M.;
    • Durmo, R.;
    • Marcheselli, L.;
    • Mantoan, B.;
    • Pironti, M.;
    • Guerra, L.;
    • Boccomini, C.;
    • Puccini, B.;
    • Pulsoni, A.;
    • Pavone, V.;
    • Arcari, A.;
    • Califano, C.;
    • Castellino, C.;
    • Bari, A.;
    • Conconi, A.;
    • Dardanis, D.;
    • Chauvie, S.;
    • Gattei, V.;
    • Del Giudice, I.
    Publication type:
    Article
    34

    CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACTION OF IBRUTINIB COMBINATION THERAPY IN MANTLE CELL LYMPHOMA (MCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 181, doi. 10.1002/hon.3163_114
    By:
    • Khouja, M.;
    • Genuardi, E.;
    • Ferrero, S.;
    • Alessandria, B.;
    • Verhagen, O. J.;
    • Homburg, C.;
    • van der Velden, V. H.;
    • Gameiro, P.;
    • Sanz, R. García;
    • Herrera, A. Medina;
    • Fronkova, E.;
    • Brüggemann, M.;
    • Dreyling, M.;
    • Hoster, E.;
    • Ladetto, M.;
    • Langerak, A. W.;
    • Darzentas, N.;
    • Pal, K.;
    • Stewart, P. J.;
    • Gonzalez de Castro, D.
    Publication type:
    Article
    35
    36
    37
    38

    SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK.

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.62_2879
    By:
    • Novak, U.;
    • Fehr, M.;
    • Schär, S.;
    • Dreyling, M.;
    • Scheubeck, G.;
    • Ramadan, S.;
    • Zucca, E.;
    • Zander, T.;
    • Hess, G.;
    • Mey, U.;
    • Ferrero, S.;
    • Mach, N.;
    • Boccomini, C.;
    • Böttcher, S.;
    • Voegeli, M.;
    • Cairoli, A.;
    • Menter, T.;
    • Dirnhofer, S.;
    • Gadient, S.;
    • Eckhardt, K.
    Publication type:
    Article
    39

    A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.59_2879
    By:
    • Ferrero, S.;
    • Moia, R.;
    • Cascione, L.;
    • Zaccaria, G. M.;
    • Rinaldi, A.;
    • Alessandria, B.;
    • Grimaldi, D.;
    • Favini, C.;
    • Evangelista, A.;
    • Schipani, M.;
    • Narni, F.;
    • Stelitano, C.;
    • Stefani, P. M.;
    • Benedetti, F.;
    • Mian, M.;
    • Casaroli, I.;
    • Zanni, M.;
    • Castellino, C.;
    • Pavone, V.;
    • Galimberti, S.
    Publication type:
    Article
    40

    UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA.

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.31_2880
    By:
    • Pulsoni, A.;
    • Tosti, M. E.;
    • Ferrero, S.;
    • Luminari, S.;
    • Dondi, A.;
    • Liberati, A. M.;
    • Cenfra, N.;
    • Renzi, D.;
    • Zanni, M.;
    • Boccomini, C.;
    • Ferreri, A. J.;
    • Rattotti, S.;
    • Zilioli, V. R.;
    • Bernuzzi, P.;
    • Bolis, S.;
    • Musuraca, G.;
    • Nassi, L.;
    • Perrone, T.;
    • Stelitano, C.;
    • Anastasia, A.
    Publication type:
    Article
    41

    UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA.

    Published in:
    Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.30_2880
    By:
    • Pulsoni, A.;
    • Tosti, M. E.;
    • Ferrero, S.;
    • Luminari, S.;
    • Dondi, A.;
    • Liberati, A. M.;
    • Cenfra, N.;
    • Renzi, D.;
    • Zanni, M.;
    • Boccomini, C.;
    • Ferreri, A. J.;
    • Rattotti, S.;
    • Zilioli, V. R.;
    • Bernuzzi, P.;
    • Bolis, S.;
    • Musuraca, G.;
    • Nassi, L.;
    • Perrone, T.;
    • Stelitano, C.;
    • Anastasia, A.
    Publication type:
    Article
    42

    FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 224, doi. 10.1002/hon.39_2630
    By:
    • Ferrero, S.;
    • Ladetto, M.;
    • Beldjord, K.;
    • Drandi, D.;
    • Stelitano, C.;
    • Bernard, S.;
    • Castagnari, B.;
    • Bouabdallah, K.;
    • Cesaretti, M.;
    • Alvarez, I.;
    • Gressin, R.;
    • Ponzoni, M.;
    • Tripodo, C.;
    • Traverse‐Glehen, A.;
    • Baseggio, L.;
    • Liberati, A.;
    • Merli, M.;
    • Tessoulin, B.;
    • Patti, C.;
    • Cabras, M.
    Publication type:
    Article
    43

    RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 153, doi. 10.1002/hon.110_2629
    By:
    • Federico, M.;
    • Mannina, D.;
    • Versari, A.;
    • Ferrero, S.;
    • Marcheselli, L.;
    • Boccomini, C.;
    • Dondi, A.;
    • Tucci, A.;
    • Guerra, L.;
    • Galimberti, S.;
    • Cavallo, F.;
    • Olivieri, J.;
    • Corradini, P.;
    • Arcaini, L.;
    • Chauvie, S.;
    • Del Giudice, I.;
    • Rusconi, C.;
    • Pinto, A.;
    • Molinari, A.;
    • Pulsoni, A.
    Publication type:
    Article
    44

    FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 224, doi. 10.1002/hon.39_2630
    By:
    • Ferrero, S.;
    • Ladetto, M.;
    • Beldjord, K.;
    • Drandi, D.;
    • Stelitano, C.;
    • Bernard, S.;
    • Castagnari, B.;
    • Bouabdallah, K.;
    • Cesaretti, M.;
    • Alvarez, I.;
    • Gressin, R.;
    • Ponzoni, M.;
    • Tripodo, C.;
    • Traverse‐Glehen, A.;
    • Baseggio, L.;
    • Liberati, A.;
    • Merli, M.;
    • Tessoulin, B.;
    • Patti, C.;
    • Cabras, M.
    Publication type:
    Article
    45

    RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.

    Published in:
    Hematological Oncology, 2019, v. 37, p. 153, doi. 10.1002/hon.110_2629
    By:
    • Federico, M.;
    • Mannina, D.;
    • Versari, A.;
    • Ferrero, S.;
    • Marcheselli, L.;
    • Boccomini, C.;
    • Dondi, A.;
    • Tucci, A.;
    • Guerra, L.;
    • Galimberti, S.;
    • Cavallo, F.;
    • Olivieri, J.;
    • Corradini, P.;
    • Arcaini, L.;
    • Chauvie, S.;
    • Del Giudice, I.;
    • Rusconi, C.;
    • Pinto, A.;
    • Molinari, A.;
    • Pulsoni, A.
    Publication type:
    Article
    46

    MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 202, doi. 10.1002/hon.2438_66
    By:
    • Morello, L.;
    • Rattotti, S.;
    • Jerkeman, M.;
    • Meerten, T.;
    • Krawczyk, K.;
    • Moita, F.;
    • Marino, D.;
    • Ferrero, S.;
    • Szymczyk, M.;
    • Aurer, I.;
    • El ‐ Galaly, T.C.;
    • Di Rocco, A.;
    • Carli, G.;
    • Defrancesco, I.;
    • Giordano, L.;
    • Carlo ‐ Stella, C.;
    • Dreyling, M.;
    • Santoro, A.;
    • Arcaini, L.
    Publication type:
    Article
    47
    48

    KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL.

    Published in:
    Hematological Oncology, 2017, v. 35, p. 94, doi. 10.1002/hon.2437_83
    By:
    • Ferrero, S.;
    • Rossi, D.;
    • Bruscaggin, A.;
    • Evangelista, A.;
    • Di Rocco, A.;
    • Spina, V.;
    • Stefoni, V.;
    • Ghione, P.;
    • Barbero, D.;
    • Monitillo, L.;
    • Gomes Da Silva, M.;
    • Santoro, A.;
    • Molinari, A.;
    • Ferreri, A.;
    • Piccin, A.;
    • Cortelazzo, S.;
    • Ladetto, M.;
    • Gaidano, G.
    Publication type:
    Article
    49
    50